38 computer-"https:" "https:" "https:" "https:" "Dr" "UCL" research jobs at King's College London
Sort by
Refine Your Search
-
at King’s College London within the Personalised Medicine team led by Dr Ahmad Al Khleifat. Our team currently include several staff and students and we have extensive experience in the development of genomic
-
supporting role in delivering a complex, multidisciplinary research programme that investigates cilia as a novel therapeutic target in Type 1 diabetes, ensuring that day-to-day experimental work runs
-
biomedical computing at the School of Biomedical Engineering & Imaging Sciences. The work will be done in close collaboration with a multidisciplinary team at KCL, UCL and clinicians at Great Ormond Street
-
place. We are delighted to announce exciting new opportunities to join our community. EMBRACE is a visionary, multicomponent international research programme, the first of its kind in the world
-
About us: Dr Teodora Trendafilova is supported by a Wellcome Early Career Fellowship. Her research aims to improve our understanding of the neurobiology of arthritis pain, focusing on the dynamic
-
& Sciences (SCMMS) provides an outstanding multi-disciplinary environment for the pursuit of cutting-edge cardiovascular and metabolic research (https://www.kcl.ac.uk/scms ). We study the fundamental molecular
-
Manger Dr Eileen Brobbin, who is based at King’s College London. This is a full-time post and you will be offered a fixed term contract of 10 months. Research staff at King’s are entitled to at least 10
-
. Fellowships provide a competitive salary and up to £30,000 in research expenses for 18–24 months, enabling fellows to establish a distinctive research programme and prepare competitive applications
-
will also be working closely with the Project Manger Dr Eileen Brobbin, who is based at King’s College London. This is a full-time post and you will be offered a fixed term contract of 10 months
-
Academic group. About The Role Applications are invited for a fixed-term position (full-time, 1.0 FTE) in the group of Dr Agostino Cilibrizzi at the Institute of Pharmaceutical Science (IPS), King’s College